Such is the case with the prominent JAK2 inhibitor Ruxolitinib, which proved to be temporarily effective in early stages of clinical trials, yet later it induced resistance mechanisms and various side effects like thrombocytopenia and reactivation of opportunistic infections (Nair et al., 2023). The gene discussed is JAK2; the disease is Opportunistic infection.